160 related articles for article (PubMed ID: 36335089)
1. UM171 cooperates with PIM1 inhibitors to restrict HSC expansion markers and suppress leukemia progression.
Hu A; Gao J; Varier KM; Gajendran B; Jiang F; Liu W; Wang C; Xiao X; Li Y; Zacksenhaus E; Ali S; Ben-David Y
Cell Death Discov; 2022 Nov; 8(1):448. PubMed ID: 36335089
[TBL] [Abstract][Full Text] [Related]
2. UM171 suppresses breast cancer progression by inducing KLF2.
Ran X; Hu A; Kuang Y; Wang C; Liu W; Xiao X; Zacksenhaus E; Yu X; Ben-David Y
Breast Cancer Res Treat; 2024 Jun; ():. PubMed ID: 38874684
[TBL] [Abstract][Full Text] [Related]
3. Lovastatin inhibits erythroleukemia progression through KLF2-mediated suppression of MAPK/ERK signaling.
Gao J; Hu J; Yu F; Wang C; Sheng D; Liu W; Hu A; Yu K; Xiao X; Kuang Y; Zacksenhaus E; Gajendran B; Ben-David Y
BMC Cancer; 2023 Apr; 23(1):306. PubMed ID: 37016335
[TBL] [Abstract][Full Text] [Related]
4. KLF2 inhibits Jurkat T leukemia cell growth via upregulation of cyclin-dependent kinase inhibitor p21WAF1/CIP1.
Wu J; Lingrel JB
Oncogene; 2004 Oct; 23(49):8088-96. PubMed ID: 15361832
[TBL] [Abstract][Full Text] [Related]
5. 1,25-Dihydroxyvitamin D3 induces differentiation of a retinoic acid-resistant acute promyelocytic leukemia cell line (UF-1) associated with expression of p21(WAF1/CIP1) and p27(KIP1).
Muto A; Kizaki M; Yamato K; Kawai Y; Kamata-Matsushita M; Ueno H; Ohguchi M; Nishihara T; Koeffler HP; Ikeda Y
Blood; 1999 Apr; 93(7):2225-33. PubMed ID: 10090931
[TBL] [Abstract][Full Text] [Related]
6. UM171 promotes expansion of autologous peripheral blood hematopoietic stem cells from poorly mobilizing lymphoma patients.
Wen R; Dong C; Xu C; Zhao L; Yang Y; Zhang Z; Chen Y; Duan L; Chen H; Yang Z; Zhang B
Int Immunopharmacol; 2020 Apr; 81():106266. PubMed ID: 32062079
[TBL] [Abstract][Full Text] [Related]
7. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.
Harada M; Benito J; Yamamoto S; Kaur S; Arslan D; Ramirez S; Jacamo R; Platanias L; Matsushita H; Fujimura T; Kazuno S; Kojima K; Tabe Y; Konopleva M
Oncotarget; 2015 Nov; 6(35):37930-47. PubMed ID: 26473447
[TBL] [Abstract][Full Text] [Related]
8. ERK activation via A1542/3 limonoids attenuates erythroleukemia through transcriptional stimulation of cholesterol biosynthesis genes.
Yu F; Gajendran B; Wang N; Sample KM; Liu W; Wang C; Hu A; Zacksenhaus E; Hao X; Ben-David Y
BMC Cancer; 2021 Jun; 21(1):680. PubMed ID: 34107900
[TBL] [Abstract][Full Text] [Related]
9.
Alsubaie M; Matou-Nasri S; Aljedai A; Alaskar A; Al-Eidi H; Albabtain SA; Aldilaijan KE; Alsayegh M; Alabdulkareem IB
Oncol Lett; 2021 Aug; 22(2):622. PubMed ID: 34267815
[TBL] [Abstract][Full Text] [Related]
10. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
[TBL] [Abstract][Full Text] [Related]
11. Relationship between cyclin D1 and p21(Waf1/Cip1) during differentiation of human myeloid leukemia cell lines.
Ullmannová V; Stöckbauer P; Hradcová M; Soucek J; Haskovec C
Leuk Res; 2003 Dec; 27(12):1115-23. PubMed ID: 12921950
[TBL] [Abstract][Full Text] [Related]
12. Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration.
Grundler R; Brault L; Gasser C; Bullock AN; Dechow T; Woetzel S; Pogacic V; Villa A; Ehret S; Berridge G; Spoo A; Dierks C; Biondi A; Knapp S; Duyster J; Schwaller J
J Exp Med; 2009 Aug; 206(9):1957-70. PubMed ID: 19687226
[TBL] [Abstract][Full Text] [Related]
13. Stat6 cooperates with Sp1 in controlling breast cancer cell proliferation by modulating the expression of p21(Cip1/WAF1) and p27 (Kip1).
Wei M; Liu B; Gu Q; Su L; Yu Y; Zhu Z
Cell Oncol (Dordr); 2013 Feb; 36(1):79-93. PubMed ID: 23184467
[TBL] [Abstract][Full Text] [Related]
14. Lysine-specific demethylase 1A restricts ex vivo propagation of human HSCs and is a target of UM171.
Subramaniam A; Žemaitis K; Talkhoncheh MS; Yudovich D; Bäckström A; Debnath S; Chen J; Jain MV; Galeev R; Gaetani M; Zubarev RA; Larsson J
Blood; 2020 Nov; 136(19):2151-2161. PubMed ID: 32582923
[TBL] [Abstract][Full Text] [Related]
15. N-ras oncogene-induced gene expression in human hematopoietic progenitor cells: upregulation of p16INK4a and p21CIP1/WAF1 correlates with myeloid differentiation.
Shen S; Passioura T; Symonds G; Dolnikov A
Exp Hematol; 2007 Jun; 35(6):908-19. PubMed ID: 17533045
[TBL] [Abstract][Full Text] [Related]
16. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
[TBL] [Abstract][Full Text] [Related]
17. Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma.
De Smedt R; Morscio J; Reunes L; Roels J; Bardelli V; Lintermans B; Van Loocke W; Almeida A; Cheung LC; Kotecha RS; Mansour MR; Uyttebroeck A; Vandenberghe P; La Starza R; Mecucci C; Lammens T; Van Roy N; De Moerloose B; Barata JT; Taghon T; Goossens S; Van Vlierberghe P
Blood; 2020 May; 135(19):1685-1695. PubMed ID: 32315407
[TBL] [Abstract][Full Text] [Related]
18. Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells.
Beharry Z; Zemskova M; Mahajan S; Zhang F; Ma J; Xia Z; Lilly M; Smith CD; Kraft AS
Mol Cancer Ther; 2009 Jun; 8(6):1473-83. PubMed ID: 19509254
[TBL] [Abstract][Full Text] [Related]
19. Constitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia.
Bellon M; Lu L; Nicot C
Blood; 2016 May; 127(20):2439-50. PubMed ID: 26813676
[TBL] [Abstract][Full Text] [Related]
20. Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia.
Goldberg L; Tijssen MR; Birger Y; Hannah RL; Kinston SJ; Schütte J; Beck D; Knezevic K; Schiby G; Jacob-Hirsch J; Biran A; Kloog Y; Marcucci G; Bloomfield CD; Aplan PD; Pimanda JE; Göttgens B; Izraeli S
Blood; 2013 Oct; 122(15):2694-703. PubMed ID: 23974202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
